Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China Approves SinoVac's CoronaVac, As 50.6% Efficacy Reported

Slow Roll-Out Despite Looming New Year Holiday

Executive Summary

SinoVac has obtained conditional approval in China for its COVID-19 vaccine CoronaVac, while new clinical data released by the company show a large difference in protection rates in two separate trials, in one case barely above the WHO threshold.

You may also be interested in...



Coronavirus Notebook: EMA Begins Rolling Review of Sinovac Vaccine, Looks At Comirnaty In 12-15-Year Age Group

Moderna and Sweden are donating vaccines to the COVAX Facility, and an African trial is investigating a combination of nitazoxanide and ciclesonide in people with mild-to-moderate COVID-19.

Bharat Biotech Gets Shot In Arm With 81% Efficacy For COVID-19 Vaccine

Bharat Biotech’s COVID-19 vaccine has shown 80.6% efficacy in interim data from Phase III clinical trials, slightly better than the 79.3% reported by Sinopharm and significantly higher than Sinovac’s 50.6% for their vaccines based on similar technology. Supply deals are already on the way, with Brazil having signed up for 200 million doses.

One Year On: WHO Concludes Wuhan Probe; CanSino Vaccine 66% Effective

A WHO team concludes a high-profile investigation in Wuhan, where the first coronavirus cases surfaced over a year ago, while a single-dose vaccine from China's CanSino is on the way.

Topics

Related Companies

UsernamePublicRestriction

Register

SC143780

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel